Beam Therapeutics Inc. (BEAM)

US — Healthcare Sector
Peers: AGIO  DNLI  RXRX  IBRX  RCUS  ETNB  COGT  MLYS  IDYA  GLPG 

Automate Your Wheel Strategy on BEAM

With Tiblio's Option Bot, you can configure your own wheel strategy including BEAM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard
BEAM, MRNA
Published: March 31, 2025 by: Invezz
Sentiment: Negative

Biotech investors are grappling with fresh uncertainty following the abrupt resignation of Dr. Peter Marks, a key figure in the US Food and Drug Administration.

Read More
image for news Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance
BEAM
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Neutral

The FDA clears Beam Therapeutics' investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency in the United States.

Read More
image for news BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity
BEAM
Published: March 10, 2025 by: Benzinga
Sentiment: Positive

On Monday, Beam Therapeutics Inc. BEAM announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical proof-of-concept as a potential treatment for alpha-1 antitrypsin deficiency (AATD) and for in vivo base editing.

Read More
image for news Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity
Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates
BEAM
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive

BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.

Read More
image for news Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts
BEAM
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial of BEAM-101; Dosing of 30 Patients and Updated Data Expected by Mid-2025 Initial Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency Expected in First Half 2025 Dosing Expected to Initiate in Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type 1a in Early 2025 IND-enabling Studies of ESCAPE Nongenotoxic Conditioning Approach Ongoing; Healthy Volunteer Study of BEAM-103 Antibody Expected to Initiate by Year-end Ended Fourth Quarter 2024 with $850.7 Million in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans …

Read More
image for news Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts
Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences
BEAM
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:

Read More
image for news Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

About Beam Therapeutics Inc. (BEAM)

  • IPO Date 2020-02-06
  • Website https://www.beamtx.com
  • Industry Biotechnology
  • CEO John Evans
  • Employees 393
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.